DD
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Eltp, Jazz has been on my mind ever since I sold before the massive climb. I won't make that same mistake again!
DMHI needs more press. I think their CEO, George England, is slowly but surely building a valuable company here. And slow but sure is the only way to build a company. IMO, DMHI will come through, just will take time. It will be interesting to see how DMHI is received at the upcoming North American Spine Society 11th Annual Evidence & Technology Spine Summit on February 26, 2015. It's a big venue with potential for massive exposure for DMHI.
The real value here is if a big EMR wants the technology platform already set up by DMHI. For example, Athenahealth bought out Epocrates. The fact of the matter is, EMR's are going mobile and DMHI has the set up. Possible partnerships on the horizon? Just saying....this is not dead!!!
Awesome! I'm with you: 8.25 seems more than reasonable given that proenzyme therapy may just become a replacement for the chemotherapeutic treatment of cancer.
Exactly: "Know what you own." Respect the peope of Propanc and their product. The Propanc group has put together a venture that is actually priceless. But everything has a price. These guys are good at what they do and they have a great multidisciplinary team. I have great confidence they will see their products through to FDA approval. It will have been eight long years for them, and they won't give up this close to the finish line. I wouldn't sell one share for 10 cents, much less the others I have stacked on top of my first. To reiterate MONEYMADE, "know what you own."
insert-text-here
SLIDE 3
BUY THE ASK. YOU WILL MISS THIS RIDE IF BID SITTING. ITS GOING TO TAKE OFF THROUGH RESISTANCES SOON>
WAKE UP AND SEE THE VALUE IN PROPANC BEFORE IT LEAVES PENNIES INVEST=PAY OFF
Propanc is Already the Complete Investment Package: 5 Key Points
1. Potential clinically proven therapeutic option in cancer treatment and prevention.
?
2. Multiple effects on cancerous cells to achieve a durable clinical response.
?
3. Encouraging data from patient treatment and scientific research over 15 years.
?
4. Unique intellectual property portfolio building knowledge of pro-enzymes in cancer.
?
5. Growing demand for new cancer treatments, over 10 million annual deaths by 2020.
?
Source: http://www.propanc.com/download/propanc-investor-presentation-jan-2015.pdf (Slide 23)
PRP Limited Human Testing Underway: SURVIVAL + SAFE
"Our lead product, PRP, is a novel, patented once daily suppository formulation of proteolytic proenzymes. In limited human testing as outlined earlier, supplemented by laboratory research at the Universities of Bath and Granada on the mechanism of action of the proenzyme mixture, evidence has been obtained which suggests PRP may be effective against a range of solid tumors.....In addition to possibly extending survival, the limited human testing showed no observable severe, or even serious adverse reactions and can be easily self-administered. Most cancer treatments currently on the market suffer from limitations of excessive toxicity or the development of resistance, limiting the extent to which they can be used chronically to control cancer over the long term. Whilst the clinical findings with PRP are early and subject to confirmation in future clinical trials, these data gathered to date, together with the observation that no evidence has been observed of the development of resistance by the cancer to PRP, suggest that PRP may be suitable for long term, chronic therapy."
Limited Human Testing Already Complete: PRP!!!!!!!!!!!
"Our lead product, PRP, is a novel, patented once daily suppository formulation of proteolytic proenzymes. In limited human testing as outlined earlier, supplemented by laboratory research at the Universities of Bath and Granada on the mechanism of action of the proenzyme mixture, evidence has been obtained which suggests PRP may be effective against a range of solid tumors.....In addition to possibly extending survival, the limited human testing showed no observable severe, or even serious adverse reactions and can be easily self-administered. Most cancer treatments currently on the market suffer from limitations of excessive toxicity or the development of resistance, limiting the extent to which they can be used chronically to control cancer over the long term. Whilst the clinical findings with PRP are early and subject to confirmation in future clinical trials, these data gathered to date, together with the observation that no evidence has been observed of the development of resistance by the cancer to PRP, suggest that PRP may be suitable for long term, chronic therapy."
Source: insert-text-here
Propanc is revolutionary: with companies and ideas that are revolutionary, it takes some time for everyone to catch up with its present value and its potential value, both in terms of $$ and in terms of contribution to humanity. We are waiting for everyone to accept the reality of Propanc.
Just imagine: Propanc's drug-line proves a safe and efficacious replacement for chemotherapy, i.e. fewer side effects=better quality of life with same or better endpoint. Millions of people benefit not to the potential PPS--sky is the limit.
FDA's Required Proof of Safe + Efficacious: It's good to know that Propanc has Dr. John Smyth on board. He serves on the Expert Oncology Advisory Group to the European Drug Licensing Board!
Propanc's Klaus Kutz's: His experience with "successful world-wide registration of multiple important Sandoz’ compounds by preparation of multiple NDAs (New Drug Applications) and Expert reports (including Written Summary), as well as the preparation of multiple INDs (Investigational New Drug Applications) for Sandoz Pharma Ltd and Sanofi Research" gives me confidence that the human trials are in expert hands.
FDA Accelerated Approval of Propanc? IMO, Propanc's PRP may be eligible for FDA Accelerated Approval.
See below for a thorough review of the FDA oncology drug approval process!
insert-text-here
NICDE BUY KINDO!!
Look at that bid: 3,020,000 for .009.
Someone wants in! This is gonna take off soon:)
Propanc's PRP: Proven Anti- Tumor Activity in Mice
See: www.propanc.com/download/propanc-investor-presentation-jan-2015.pdf
SLIDE 10
Propanc's PRP – DCM: Significantly Reduces Angiogenesis in Mice
insert-text-here
SLIDE 12
Propanc's PRP – DCM: Significantly Reduces Angiogenesis in Mice
See: http://www.propanc.com/download/propanc-investor-presentation-jan-2015.pdf
SLIDE 12
Propanc's PRP: Proven Anti- Tumor Activity in Mice
See: http://www.propanc.com/download/propanc-investor-presentation-jan-2015.pdf
SLIDE 10
New research partnership: Biopathology and Regenerative Medicine Institute (IBIMER), University of Granada, Granada, Spain
See: http://www.propanc.com/download/propanc-investor-presentation-jan-2015.pdf
SLide 14
Propanc's investor presentation certainly provides some valuable information and only heightens my confidence in the company! I noticed it online about a week ago.
Propanc Investor Presentation 01/2015. Fantastic!
http://www.propanc.com/download/propanc-investor-presentation-jan-2015.pdf
Animal efficacy studies near completed. See January 2015 investor report here. Animal study results begin slide 10. Anticipated timelines slide17! Huamn trials Q4 2015
http://www.propanc.com/download/propanc-investor-presentation-jan-2015.pdf
MoneyMade,
Thanks for sharing about your conversation with Propanc. I share in the confidence he impressed upon you. What brings me a high degree of assurance about the future of Propanc are the academic/university, national and international policy/scientific organizations and associations, and public companies with which Propanc's Scientific Board and Board of Directors have been affiliated with now or in the past. The quality and quantity of these affiliations are impressive:
1. University of Bath, Center foir Regenerative Medicine, Department of Biology and Biochemistry
2. FIBAO
3. UK Committee on Safety of Medicines
4. Expert Advisory Group for Oncology & Haematology for the Commission on Human Medicines
5. Expert Oncology Advisory Group to the European Drug Licensing Board
6. Royal College of Physicians of Edinburgh and London
7. Fellow of the Royal Society of Edinburgh
8. Past-president of the European Society of Medical Oncolog
9. President of the Federation of European Cancer Societies.
10. Management at Abbott Laboratories
11. Management Beecham Pharmaceuticals
12. Medical Director of the Dove Clinic for Integrated Medicine
13. Founder-Chairman of the British Medical Acupuncture Society
14. Co-Founder of the Centre for the Study of Complementary Medicine
15. Primary Fellow of the Royal College of Surgeons, Edinburgh
16. Sandoz Pharma Ltd
17. Professor of Medicine at the University of Bonn, Germany.Sanofi Research
I have zero doubt in the competence of Propanc to obtain the financial resources needed to carry out successful human trials and that those trials (especiall of PRP) will be successful. Who know what else Propanc has coming down the pipeline. This R&D is only in it’s infancy but looks primed for a bright and successful future. I’m working hard to establish a good position with this company to be ready for up and coming PR’s and before Propanc is discovered by the masses (as the previous post noted).
<Why Propanc will be successful>
Propanc's John Smyth is one of three that sit on Propanc's Scientific Advisory Board. Professor Smyth also serves on the Expert Oncology Advisory Group to the European Drug Licensing Board. If he, in any way, evaluated that PRP was not highly likely to successfully pass human trials and eventually reach the market, do you think he would still be involved with PROPANC? This is a guy who is also a past-president of the European Society of Medical Oncology and was from 2005 – 2007 President of the Federation of European Cancer Societies
Cover Story Cancer World: Propanc's Prof. John Smyth
This cover story on Professor John Smyth of Propanc's Scientific Advisory board provides some insight into what's driving Propanc and why it will not fail! Industry meets academics.
http://www.cancerworld.org/pdf/1079_06_13_cw8_coverstory.pdf
MELBOURNE, Australia, Sept. 22, 2014 /PRNewswire/ -- Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company that focuses on the development of new and proprietary treatments for cancer patients, is pleased to announce it has executed an equity purchase agreement (the "EPA") with Southridge Partners II, L.P., an institutional investor, in the amount of $5 million, which will create significant growth capital for Propanc, enabling the execution of its business plan, on favorable terms.
Under terms of the EPA, Propanc has the right, but not the obligation to sell, from time to time, up to $5 million of its common stock to Southridge by submitting a "Draw Down" notice in an amount that the company determines. In order to draw down on the EPA, Propanc will need to file and register an S-1 registration statement with the Securities and Exchange Commission.
"We are pleased to be partnering with Southridge, an institutional investor with a long, reliable history of providing capital to the small cap space. We believe this capital will be sufficient to fund our growth strategy, enabling us to progress our product candidates through preclinical development and into clinical trials," said James Nathanielsz, Propanc's Chief Executive Officer. "The terms of this agreement are favorable to our shareholders and provide Propanc with the best opportunity to execute its business plan and deliver long-term shareholder value. We are grateful for the confidence Southridge has shown in Propanc, our management team, and our strategy."
"Propanc's business plan provided us with the confidence necessary to provide growth capital. We are excited to partner with Propanc and its seasoned management team as they execute their strategy," commented Stephen Hicks, Principal and CEO of Southridge Partners II, L.P.
About Southridge
Southridge is a diversified financial holding company specializing in direct investment and advisory services to small and middle market companies. Since 1996, the structured finance team has made direct investment of over $1.7 billion into growth companies worldwide. Southridge's expertise lies in an ability to customize a financing plan for the prospective client and then to execute on that plan without failing.
About Propanc:
We are a development stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Together with our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our leading products are variations upon our novel formulation and involve or employ pro-enzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of our technology, we intend to submit our pro-enzyme treatment to the rigorous, formal non-clinical and clinical development and trial processes required to obtain the regulatory approval necessary to commercialize it and any product(s) derived and/or to be derived therefrom.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In the future, we intend to development our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, please visit: www.propanc.com.
Professor Klaus Kutz, M.D., CMO--He will complete successful human trials. Look at his CV.
Professor Kutz has ten years of experience as independent consultant in Clinical Pharmacology and Safety for pharmaceutical companies and clinical research organizations. His specialty over the last six years is Oncology, including preparation of multiple NDAs and INDs for small and medium sized pharmaceutical companies. He has prepared, organized and reported clinical Phase I studies in oncology and Phase II studies in different cancer indications (prostate, gastric, ovarian, small cell lung cancer) and Non-Hodgkin Lymphomas.
Professor Kutz has more than 12 years experience as Head of Clinical Pharmacology with world-wide responsibilities for Phase I and Clinical Pharmacokinetics in two internationally operating pharmaceutical companies, setting up and restructuring international Clinical Pharmacology departments. His achievements include the successful world-wide registration of multiple important Sandoz’ compounds by preparation of multiple NDAs (New Drug Applications) and Expert reports (including Written Summary), as well as the preparation of multiple INDs (Investigational New Drug Applications) for Sandoz Pharma Ltd and Sanofi Research. A specialist for Internal Medicine, Gastroenterology, and Clinical Pharmacology, he is also Professor of Medicine at the University of Bonn, Germany.
DrMerlot is right. The scaredy cats are gone. HIT THE ASK!!! We can save time. Propanc will eventually climb back beyon .019, but we can save time now if we HIT THE ASK. The low doesnt need to be as low as in the past and then the high will be higher than in the past
It will not go that low. People are not going to sell at that price. The FearFul sellers are leaving now. The non-emotional traders are holding because we know this company has VALUE and huge profit potential. Buy in now at the ask, and you will drive it back up. Thats how this works.
Buying anything below .01 is a steal and will pay off big time!
No, it will continue a downward slide until people start hitting the asking price. Then we build momentum for the up swing. Its trending, but doesnt have to hit the low before the .019 bounce.
Hitting the ask may cost a few shares but will pay off big time in the waiting. We want PPCH up to its proper price point (.01-.019) today. HIT THE ASK AND BUILD MOMENTUM!
Predicted close today at .014 imo
Yup, but at some point, maybe on the next climb, we will be staying in the highlands- human trials around the corner. Or perhaps an acquisition at .!. Merk, Roche, Pfizer?
Give Ppch respect: hit the ask. It'll pay off quicker and bigger.
No fear. Propanc will rise again because their value is at the top of the hierarchy: providing life to the sick dying. PRP is revolutionary cancer treatment.
We are in the valley. We've climbed two peaks in 2 months . Last one was .019. Looking ahead, the next peak looks to sit at .05. The map I'm using is the 1 month chart. Get ready for a big climb.
90 days: If Propanc gets Orphan Drug Designation, human trials can start in less than 90 days! CMO of Propanc is talking about going for the ODD for financial incentives! No 5-7 years waiting to start!